Dualyx: restoring the body’s balance in autoimmune diseases
Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The method uses llama-derived antibodies to flip a master switch and create regulatory T cells, which help restore order to overzealous immune systems.
Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions
Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections. Along […]
Drug development trends: from common to orphan indications… and back again?
Over the past few decades, pharma has gradually shifted its target patient focus for newly launched drugs from large to niche populations. What has caused this trend, and is the pendulum of drug development swinging back again?
Genetic blindness: shining a light on Stargardt for future cures
The arrival of gene therapy in the ‘90s brought hope for the treatment of genetic diseases. In recent years, new and emerging technologies have allowed us to overcome initial limitations, opening up the potential of tackling health conditions that were impossible to treat just a few years ago. Stargardt disease – a form of inherited blindness – is one such genetic condition, where researchers in the EU project StarT are working on novel gene therapy approaches to eventually help patients.
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
Started clinical trial with lead candidate RJx-01 for treating sarcopenia Expands the team and moved to new offices and lab Diepenbeek, Health Campus, Belgium, 29 March 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, today provides an update on its development pipeline and strategy. Rejuvenate has commenced its first Phase […]
Eye implant from iSTAR Medical keeps glaucoma under control
Glaucoma is the leading cause of irreversible blindness, affecting around 100 million people worldwide. Good news though: the innovative implant MINIject – developed by Wavre-based company iSTAR Medical – has the capacity to prevent progression of the eye disease. The first commercial MINIject implantations are currently being done in Germany, with other European countries to follow soon and a trial in the US underway.
V-Bio Ventures’ Portfolio Company Precirix raises EUR 80 million in Series B to advance its pipeline of precision radiopharmaceuticals
Ghent, Belgium, 16 March 2022 – V-Bio Ventures today announced the completion of a EUR 80 million Series B round of its portfolio Company Precirix NV led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. “We are delighted to announce this major milestone and are grateful for the strong investor support. The […]
ElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer
Mechelen, Belgium, January 25, 2022 – Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.
V-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals
Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.
Rejuvenate Biomed: Expanding peoples’ health spans by boosting cell resilience
Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.
Confo-dently into the future!
Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, launched in 2015 as a spin-off of the Vrije Universiteit Brussel (VUB) and VIB, is now taking the big step from the preclinical to the clinical stage with a GPCR drug for neuropathic pain.
Successes and setbacks for women’s health specialist Mithra
It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Things are moving fast for Flamingo Therapeutics, a Leuven-based biotech company developing innovative RNA-targeted cancer therapies. The start-up is a pioneer in the field of lncRNAs, a large and untapped class of disease-causing targets within the so-called ‘dark matter’ of the human genome.
Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging
Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
EsoBiotec ready to transform cell therapy cancer treatments
EsoBiotec, a recently founded biotech company, announces a EUR 6 million pre-series A round comprised of non-dilutive funding from the Walloon Government combined with seed investments from venture capitalist Thuja Capital and regional funding agencies SRIW Life Sciences and Sambrinvest. EsoBiotec is developing next generation cell therapy cancer treatments and offering previously unattainable treatment options […]